GHK-Cu

Background

GHK was first isolated by Loren Pickart in 1973 from human plasma. He observed that older plasma had less GHK than younger plasma and that adding GHK back restored some markers of "younger" tissue behavior in cultured cells. The copper-bound form (GHK-Cu) is the physiologically active species; the peptide acts as a copper-shuttling chaperone.

Plasma levels decline from roughly 200 ng/mL in young adults to about 80 ng/mL by age 60. This age-related decline is one of the most-cited motivations for exogenous GHK-Cu use.

Mechanism in depth

GHK-Cu acts through several overlapping routes:

1. Copper delivery to copper-dependent enzymes — including lysyl oxidase (crosslinks collagen and elastin) and superoxide dismutase (antioxidant defense).
2. Direct gene expression modulation — broad-array studies show GHK-Cu modifies expression of thousands of genes, with the strongest signals in DNA repair, antioxidant defense, and tissue remodeling programs.
3. Fibroblast and keratinocyte signaling — stimulates proliferation and migration in vitro at low nanomolar concentrations.
4. Stem cell signaling in hair follicles — increases dermal papilla cell viability and follicle size in cultured human follicles.

The breadth of effects has led some to characterize GHK-Cu as a "master regulator" — a description that is descriptively accurate but mechanistically still being worked out.

Human evidence

Topical evidence is the strongest:

• Multiple controlled trials of GHK-Cu cream show improvements in skin firmness, fine lines, and photodamage versus vehicle, typically over 12 weeks.
• Wound healing trials in venous and diabetic ulcers show modest improvements in closure rate when GHK-Cu is included in dressings.
• Several small studies of GHK-Cu shampoo or scalp formulations report improvements in hair density and shaft thickness, though not as dramatic as approved hair-loss treatments.

Injectable / systemic human evidence is much thinner. Most "results" reported anecdotally come from research-peptide users rather than controlled trials.

Animal evidence

Extensive rodent and rabbit studies cover:

• Accelerated wound closure (full-thickness and ischemic wounds)
• Reduced fibrosis in lung and liver injury models
• Hair regrowth in mouse depilation models
• Anti-tumor signals in some cancer cell lines (cell-culture only)

Findings are reproducible across labs and have stood up to several decades of replication attempts.

Stack synergy

Frequently paired with:

• BPC-157 / TB-500 — complementary tissue-repair programs; commonly stacked for connective tissue recovery
• Topical retinoids or vitamin C — additive cosmetic effects, though no robust comparative trial data
• Microneedling — used immediately post-procedure to enhance delivery; this is consistent with topical penetration data

Avoid combining GHK-Cu with topical agents that chelate copper (e.g., some peeling acids in the same application window) — the copper handoff to enzymes is the active mechanism.

Open questions

• Does subcutaneous GHK-Cu produce systemic effects beyond what topical use achieves, and at what dose?
• What is the optimal copper-to-peptide ratio for different indications?
• Long-term safety of chronic injectable use in healthy adults is uncharacterized.
• Reported gene-expression effects in cultured fibroblasts — do they translate quantitatively to in vivo skin at clinically meaningful magnitudes?